Wojciech Tomikowski

Empowering Companies with AI-Driven Decision Intelligence 🟣 OMNIVISER boosts decision-making processes in companies through proactive AI agents that cut costs and grow revenue. They reduce resource waste, identify growth opportunities, and help implement changes that maximize ROI. It's like having a big picture never seen before which allows you to be 3 steps ahead all the time. Let's talk!

Strategic guidance for breath-based diagnostic technology development Preparation for main market listing transition Growth strategy and commercialization planning

Building CEE leading biotechnology portfolio company with global reach. Regulatory Milestone: Achieved registration of first innovative pharmaceutical drug in Polish history (tramadol combination therapy). Portfolio Scale: Operationally managing 11 active biotechnology projects across subsidiary companies, 5 based in the USA and 4 in Europe. International Expansion: Established Vasa Therapeutics Inc. in the United States with 5 cardiology programs, two in clinical development. Funding Success: Secured multi-million funding rounds for breakthrough life science, medical device, and digital portfolio. Strategic Partnerships: Negotiating major pharmaceutical partnerships for late-stage development programs. IP Development: Built portfolio of proprietary intellectual property across multiple therapeutic areas. Team Leadership: Assembled world-class scientific team led by internationally recognized Life Sciences experts. Current Projects: • Vasa Therapeutics Inc.: Revolutionary heart failure, sarcopenia, and arrhythmia treatments • Novel GLP-1 combination therapies addressing muscle loss • Veterinary applications of human therapeutics • Breakthrough cardiovascular interventions Key Achievement: Positioning Vasa to become the largest Polish-owned biotechnology success story.

Strategic oversight of renewable energy project development. Advisory role in wind, solar, and bioenergy investments. Public company governance and strategic planning.

Strategic advisory to the Board.

Developed early-stage technology companies and commercialized academic research. Gaming Sector Focus: Identified, funded, and developed mobile and PC gaming companies from concept to market launch. Academic Partnerships: Commercialized university research projects, particularly in biotechnology and materials science. NewConnect Listings: Successfully took multiple portfolio companies public on Warsaw's alternative trading platform. Team Development: Mentored young entrepreneur teams, providing strategic guidance and operational support. Exit Strategy: Developed and executed liquidity strategies for early-stage investments. Key Achievement: Built a successful bridge between academic innovation and commercial markets, creating multiple successful technology companies.

Delivered exceptional returns through portfolio restructuring and strategic investments. Portfolio Rescue: Led restructuring of underperforming investments, returning multiple companies to profitability. Star Investment: Led acquisition and development of a technology company that achieved 5x return in 24 months and exited via a private transaction on a public market. Conflict Resolution: Resolved complex shareholder disputes through strategic buyouts and operational improvements. Deal Sourcing: Identified and executed new investments in high-growth technology and service sectors. Value Creation: Applied operational expertise to drive portfolio company performance improvements Strategic Exit: Left partnership due to disagreements over fund strategy and capital allocation. Key Achievement: Generated top-quartile returns in a challenging private equity environment while establishing a reputation for operational value creation.

Built M&A advisory practice during global financial crisis. Entrepreneurial Launch: Co-founded boutique M&A advisory firm with finance sector partner during unprecedented market downturn. Crisis Navigation: Sustained business operations through a 3-year global financial crisis when deal activity virtually ceased. Service Development: Created comprehensive transaction advisory services including valuation, due diligence, and deal structuring. Market Recovery: Achieved breakthrough transaction success as markets recovered, establishing a sustainable client base. Sector Expertise: Developed specialization in small/mid-market transactions across technology, manufacturing, and consumer goods. Key Achievement: Built a successful independent M&A practice from startup during the worst financial crisis in decades, demonstrating resilience and market timing.

Converted the representative office into a fully operational subsidiary. Legal & IT Structure Creation: Established a complete Russian legal entity with full operational capabilities, regulatory compliance, tax optimization, and a complete IT solution. Market Development: Created go-to-market strategy for Gerber products in Russian Federation. Key Achievement: Successfully launched full Russian operations, creating a foundation for Novartis long-term presence in a major Eastern European market.

Co-managed local operations and strategic M&A initiatives in high-growth market. Dual Responsibility: Combined local business management with corporate development and M&A transaction leadership. Market Entry Strategy: Developed China market penetration strategies for Gerber baby food products in the world's largest demographic market. Transaction Management: Due diligence and negotiation processes for strategic acquisitions and partnerships. Regulatory Navigation: Built relationships with Chinese regulatory authorities to ensure compliance and market access. Cross-border Coordination: Managed complex international supply chains and transfer pricing arrangements. Key Achievement: Established a sustainable Chinese operations framework while identifying strategic growth opportunities through M&A.

Led major corporate restructuring delivering exceptional financial recovery Crisis Management: Inherited company with massive losses following strategic brand divestments that left 650-person organization with significantly reduced revenue base Workforce Optimization: Reduced headcount from 650 to 450 employees while maintaining operational efficiency and improving employee satisfaction Financial Turnaround: Achieved 8-10% profit margin from substantial losses within 12 months - representing multi-million USD swing in profitability Operational Excellence: Completely restructured production, sales, and R&D functions to align with new business model Product Innovation: Launched new Gerber products and improved quality standards while reducing manufacturing costs Market Recovery: Reversed declining market trends in baby food segment, restoring growth trajectory Key Achievement: Delivered fastest and most comprehensive corporate restructuring in Novartis European operations, saving business unit and preserving future jobs